US Officials Warn Wall Street of AI Cybersecurity Risks from Anthropic's Mythos Model

• La valorisation d'Anthropic a grimpé en flèche, passant de 61 milliards de dollars à 900 milliards de dollars en environ 14 mois, reflétant un intérêt sans précédent des investisseurs pour les capacités et la trajectoire de croissance de l'entreprise d'IA. • Cette envolée de la valorisation est portée par une solide performance des revenus et par la confiance des investisseurs dans les modèles d'IA et la recherche d'Anthropic, la positionnant comme un concurrent redoutable pour OpenAI sur le marché de l'IA générative. • Cette ascension rapide illustre l'intensification de la concurrence pour les capitaux dans le développement de l'IA de pointe, les grands investisseurs soutenant plusieurs startups d'IA pour diversifier leurs paris sur le potentiel transformateur de cette technologie.

• Deep Tech Week highlights The AI Collective, described as the world’s largest AI community, which connects more than 100,000 AI builders, researchers, and professionals through events, forums, and networking. • The gathering brings together startups, corporate labs, and academic groups to showcase advances in core machine learning, robotics, and applied AI, with a focus on interoperability and responsible deployment. • U.S. participation is strong, with many leading AI research labs and venture‑backed startups using the venue to announce new collaborations, model releases, and open‑source tooling.

• In the first quarter of 2026, AI‑driven insurance technology firms attracted significant capital, including Harper Group’s $47 million seed plus Series A and Indigo Technologies’ $50 million Series B, both focused on AI‑automated underwriting and claims workflows. • Platforms such as Mea Platforms, Pasito, General Magic, and Qumis raised between $4.3 million and $50 million to automate document‑heavy processes, reduce loss ratios, and compress quote and bind times for small and midsize businesses. • Investors are backing U.S.‑based vendors that use AI to scale distribution without proportional headcount growth, reduce friction in benefits selection, and improve risk selection in commercial lines.

• Meta reported $107bn in contractual commitments for Q1 2026 cloud services to fuel AI model development. • Aggressive investments include datacenter expansions and supply chain deals for AI hardware components. • Company expects AI breakthroughs later in 2026, pushing to monetize advanced research.

• Oracle released a new customer security advisory on April 30, 2026, preempting threats to AI models. • The advisory highlights a cybersecurity harbinger, urging updated security postures for AI deployments. • It signals proactive measures against novel vulnerabilities targeting generative AI systems.

• Amazon Web Services achieved its fastest growth in nearly four years, fueled by AI solutions and enterprise adoption. • Key drivers include innovations like Bedrock and Kiro amid surging cloud spending. • AI is sparking a new wave of infrastructure investments in the US market.

• SoftBank is preparing Roze AI, combining robotics, data centers, and AI infrastructure for a US IPO targeting $100B valuation. • Masayoshi Son backs the venture, with potential public listing as early as late 2026 or 2027. • Executives plan an analyst day in July, though no products or revenue plans announced yet.

• Aviatrix Inc. announced the launch of a new platform designed to contain artificial intelligence agents and enforce security controls across AI workloads without requiring changes to AI agents or code. • The platform extends Aviatrix's Cloud Native Security Fabric with two new products: Zero Trust for AI Workloads (now generally available) and Aviatrix AgentGuard (in early access), enabling IT teams to set policies that allow or deny access to external AI services and block shadow AI with allowlists. • The solution provides network-layer enforcement across workloads and regions, addressing the growing need to secure AI agents, large language model proxies, and agentic frameworks in enterprise environments.

• The Pentagon launched GenAI.mil in December 2025 as part of Project Maven, providing secure generative AI access to approximately 3 million Department of Defense staff members. • The platform embeds multiple leading AI models including Anthropic's Claude, Google's Gemini, xAI's Grok, and OpenAI's ChatGPT, enabling widespread AI adoption across military operations. • The initiative reflects the U.S. military's strategic priority to integrate advanced AI capabilities into defense operations and demonstrates significant government investment in dual-use AI technology.

• Skye AI, a home screen app for iPhone powered by artificial intelligence, raised $3.58 million in pre-seed funding while still in private testing phase. • The funding supports development of the app, which aims to enhance iPhone user experience through AI-driven features accessible directly from the home screen. • This investment highlights growing investor interest in mobile AI applications amid competition in the smartphone ecosystem.

• Sevii announced the launch of its Autonomous Cyber Swarm Defense (CSD) capability on April 28, 2026, to counter high-volume AI-driven cyber attacks at machine speed and scale. • The ADR platform deploys Agentic AI Cyber Warrior agents that detect, contain, and remediate threats in under 15 minutes, reducing analyst workloads by 95% with a fixed per-asset pricing model eliminating AI token costs. • CSD Mode features Myrmidon Defense Technology (MDT) for efficient micro-orchestration, enabling predictable budgeting without additional hires or outsourcing, as noted by Synergem Technologies CEO Frank Holt.

• Framingham, MA-based Tortugas Neuroscience raised $106 million in combined seed and Series A funding for small molecule therapies targeting neurological disorders. • Cure Ventures led the seed round, with The Column Group and AN Venture Partners co-leading Series A on April 21. • The investment accelerates development of treatments using validated biological targets, addressing unmet needs in US biotech.